Phase II Study of Luspatercept in RBC Transfusion-Dependent Patients With Myelofibrosis-Associated Anemia: Updated Results

Preliminary results for ropeginterferon alfa-2b in prefibrotic primary low/intermediate-1 risk myelofibrosis, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Phase I study evaluating selinexor + ruxolitinib in previously untreated myelofibrosis, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on management strategies for MF

Srdan Verstovsek, MD, PhD
Program Director Brady L. Stein, MD, MHS Abdulraheem Yacoub, MD Released: December 16, 2022

Results from phase II REFINE cohort 3 evaluating navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis, from ASH 2022 and reported by Clinical Care Options (CCO)